New: Introducing the Finviz Crypto Map

Emergent BioSolutions

Contributing Author

Recent Articles by Emergent BioSolutions

Aug-06	Emergent BioSolutions Reports Second Quarter 2025 Financial Results EBS GlobeNewswire
Jul-28	New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox EBS GlobeNewswire
Jul-28	Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives EBS GlobeNewswire
Jul-15	Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 EBS GlobeNewswire
Jul-08	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts EBS GlobeNewswire
Jul-02	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate EBS GlobeNewswire
Jun-23	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply EBS GlobeNewswire
Jun-20	Emergent BioSolutions Announces Addition to Russell 3000 Index EBS GlobeNewswire
Jun-05	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies EBS GlobeNewswire
May-14	Emergent BioSolutions to Participate in Upcoming Investor Conferences EBS GlobeNewswire
May-07	Emergent BioSolutions Reports First Quarter 2025 Financial Results EBS GlobeNewswire
May-01	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health EBS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.